Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | DHODH | Q02127 | 8/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616009 | 0.89 | KCNH2 (0.50) | KCNH2DHODHCYP2C9 | |
| SCHEMBL1616117 | 0.84 | KCNH2 (0.53) | KCNH2CYP2C9MAP2K1 | |
| SCHEMBL1615474 | 0.84 | KCNH2 (0.68) | KCNH2CYP2C9MAP2K1 | |
| SCHEMBL1615100 | 0.83 | KCNH2 (0.75) | KCNH2CYP2C9BRAFMAP2K1 | |
| SCHEMBL29683787 | 0.83 | KCNH2 (0.75) | KCNH2CYP2C9BRAFMAP2K1 | |
| SCHEMBL1615188 | 0.82 | KCNH2 (0.52) | KCNH2CYP2C9MAP2K1 | |
| SCHEMBL1615842 | 0.80 | KCNH2 (0.61) | KCNH2CYP2C9BRAFMAP2K1 | |
| Trifluoroacetic Acid SCHEMBL30185624 | 0.79 | KCNH2 (0.62) | KCNH2CYP2C9MAP2K1 | |
| SCHEMBL28220559 | 0.79 | MAP2K1 (0.40) | DHODHMAP2K1SPR | |
| SCHEMBL15234261 | 0.76 | KCNH2 (0.56) | KCNH2CYP2C9BRAFMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2690101-B1 | 5-Anilinoimidazopyridines and Methods of Use | GENENTECH INC (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2690101-B1 | 5-Anilinoimidazopyridines and Methods of Use | GENENTECH INC (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2690101-A1 | 5-Anilinoimidazopyridines and Methods of Use | Genentech, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690101-A1 | 5-Anilinoimidazopyridines and Methods of Use | Genentech, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2222675-B1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH INC (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2222675-B1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2222675-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | Genentech, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009085983-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085983-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885DHODH 177/4885CYP2C9 3917/4885 |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, MAP3K5, MAPKAPK5 | KCNH2 1382/4885DHODH 972/4885CYP2C9 2665/4885 |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885DHODH 177/4885CYP2C9 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.